{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:55:32Z","timestamp":1788612932964,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"FP7-HEALTH-2012-INNOVATION","award":["THALAssaemia MOdular Stratification System for personalized therapy of ?-thalassemia"],"award-info":[{"award-number":["THALAssaemia MOdular Stratification System for personalized therapy of ?-thalassemia"]}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["NIDDK-R01DK090554"],"award-info":[{"award-number":["NIDDK-R01DK090554"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["NIDDK-R01DK095112"],"award-info":[{"award-number":["NIDDK-R01DK095112"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40291-019-00383-4","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T01:33:43Z","timestamp":1548898423000},"page":"173-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges"],"prefix":"10.1007","volume":"23","author":[{"given":"Valentina","family":"Ghiaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Chappell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rivella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Breda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"issue":"9861","key":"383_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","volume":"381","author":"FB Piel","year":"2013","unstructured":"Piel FB, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142\u201351.","journal-title":"Lancet"},{"issue":"6","key":"383_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2471\/BLT.06.036673","volume":"86","author":"B Modell","year":"2008","unstructured":"Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480\u20137.","journal-title":"Bull World Health Organ"},{"issue":"2","key":"383_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.hoc.2017.11.011","volume":"32","author":"L Strocchio","year":"2018","unstructured":"Strocchio L, Locatelli F. Hematopoietic stem cell transplantation in thalassemia. Hematol Oncol Clin N Am. 2018;32(2):317\u201328.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"6","key":"383_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/MOH.0000000000000280","volume":"23","author":"F Locatelli","year":"2016","unstructured":"Locatelli F, Merli P, Strocchio L. Transplantation for thalassemia major: alternative donors. Curr Opin Hematol. 2016;23(6):515\u201323.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"383_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2013.099747","volume":"99","author":"E Angelucci","year":"2014","unstructured":"Angelucci E, et al. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811\u201320.","journal-title":"Haematologica"},{"issue":"3","key":"383_CR6","doi-asserted-by":"publisher","first-page":"e32345","DOI":"10.1371\/journal.pone.0032345","volume":"7","author":"L Breda","year":"2012","unstructured":"Breda L, et al. Therapeutic hemoglobin levels after gene transfer in beta-thalassemia mice and in hematopoietic cells of beta-thalassemia and sickle cells disease patients. PLoS One. 2012;7(3):e32345.","journal-title":"PLoS One"},{"issue":"30","key":"383_CR7","doi-asserted-by":"publisher","first-page":"10547","DOI":"10.1073\/pnas.0711666105","volume":"105","author":"A Miccio","year":"2008","unstructured":"Miccio A, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci USA. 2008;105(30):10547\u201352.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"383_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/emmm.201000083","volume":"2","author":"EA Roselli","year":"2010","unstructured":"Roselli EA, et al. Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med. 2010;2(8):315\u201328.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"383_CR9","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1172\/JCI67930","volume":"123","author":"Z Romero","year":"2013","unstructured":"Romero Z, Urbinati F, Geiger S, Cooper AR, Wherley J, Kaufman ML, Hollis RP, et al. \u03b2-globin gene transfer to human bone marrow for sickle cell disease. J Clin Investig. 2013;123(8):3317\u201330.","journal-title":"J Clin Investig"},{"issue":"2","key":"383_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/hum.2016.007","volume":"27","author":"O Negre","year":"2016","unstructured":"Negre O, et al. Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene. Hum Gene Ther. 2016;27(2):148\u201365.","journal-title":"Hum Gene Ther"},{"issue":"12","key":"383_CR11","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1182\/blood-2004-04-1427","volume":"104","author":"G Puthenveetil","year":"2004","unstructured":"Puthenveetil G, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood. 2004;104(12):3445\u201353.","journal-title":"Blood"},{"issue":"6791","key":"383_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/35017565","volume":"406","author":"C May","year":"2000","unstructured":"May C, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406(6791):82\u20136.","journal-title":"Nature"},{"issue":"5550","key":"383_CR13","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1126\/science.1065806","volume":"294","author":"R Pawliuk","year":"2001","unstructured":"Pawliuk R, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 2001;294(5550):2368\u201371.","journal-title":"Science"},{"issue":"5","key":"383_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.hoc.2017.06.010","volume":"31","author":"G Ferrari","year":"2017","unstructured":"Ferrari G, Cavazzana M, Mavilio F. Gene therapy approaches to hemoglobinopathies. Hematol Oncol Clin N Am. 2017;31(5):835\u201352.","journal-title":"Hematol Oncol Clin N Am"},{"issue":"4","key":"383_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/hum.2016.037","volume":"27","author":"J Mansilla-Soto","year":"2016","unstructured":"Mansilla-Soto J, et al. Cell and gene therapy for the beta-thalassemias: advances and prospects. Hum Gene Ther. 2016;27(4):295\u2013304.","journal-title":"Hum Gene Ther"},{"key":"383_CR16","volume-title":"Gene therapy for beta thalassemia: preliminary results from the phase I\/II Tiget-Bthal Trial of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector","author":"S Marktel","year":"2017","unstructured":"Marktel S, et al. Gene therapy for beta thalassemia: preliminary results from the phase I\/II Tiget-Bthal Trial of autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector. Atlanta: ASH 59th Annual Meeting and Exposition; 2017."},{"key":"383_CR17","volume-title":"Clinical outcomes up to 3\u00a0years following lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia in the Northstar Hgb-204 study","author":"JL Kwiatkowski","year":"2017","unstructured":"Kwiatkowski JL, et al. Clinical outcomes up to 3\u00a0years following lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia in the Northstar Hgb-204 study. Atlanta: ASH 59th Annual Meeting and Exposition; 2017."},{"key":"383_CR18","volume-title":"Results from the Hgb-207 (Northstar-2) trial: a phase 3 study to evaluate safety and efficacy of lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia (TDT) in patients with non-\u03b2\/\u03b2 genotypes","author":"M Walters","year":"2017","unstructured":"Walters M, et al. Results from the Hgb-207 (Northstar-2) trial: a phase 3 study to evaluate safety and efficacy of lentiglobin gene therapy for transfusion-dependent \u03b2-thalassemia (TDT) in patients with non-\u03b2\/\u03b2 genotypes. Atlanta: ASH 59th Annual Meeting and Exposition; 2017."},{"key":"383_CR19","first-page":"1176","volume-title":"Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease","author":"J Kanter","year":"2016","unstructured":"Kanter J, Walters MC, Hsieh MM, Krishnamurti L, Kwiatkowski J, Kamble RT, von Kalle C, Kuypers FA, Cavazzana M, Leboulch P, Joseney-Antoine M, Asmal M, Thompson AA, Tisdale JF. Interim results from a phase 1\/2 clinical study of lentiglobin gene therapy for severe sickle cell disease. San Diego: American Society of Hematology; 2016. p. 1176."},{"issue":"9","key":"383_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","volume":"376","author":"JA Ribeil","year":"2017","unstructured":"Ribeil JA, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848\u201355.","journal-title":"N Engl J Med"},{"issue":"16","key":"383_CR21","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson AA, et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. N Engl J Med. 2018;378(16):1479\u201393.","journal-title":"N Engl J Med"},{"key":"383_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exphem.2018.05.004","volume":"64","author":"K Sii-Felice","year":"2018","unstructured":"Sii-Felice K, et al. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice. Exp Hematol. 2018;64:12\u201332.","journal-title":"Exp Hematol"},{"issue":"6","key":"383_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MOH.0000000000000385","volume":"24","author":"DP Dever","year":"2017","unstructured":"Dever DP, Porteus MH. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation. Curr Opin Hematol. 2017;24(6):481\u20138.","journal-title":"Curr Opin Hematol"},{"key":"383_CR24","doi-asserted-by":"publisher","first-page":"e27873","DOI":"10.7554\/eLife.27873","volume":"6","author":"RO Bak","year":"2017","unstructured":"Bak RO, et al. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR\/Cas9 and AAV6. Elife. 2017;6:e27873.","journal-title":"Elife"},{"key":"383_CR25","volume-title":"CRISPR\/Cas9 gene-edited hematopoietic stem cell therapy for sickle cell disease","author":"VWC Yu","year":"2017","unstructured":"Yu VWC, et al. CRISPR\/Cas9 gene-edited hematopoietic stem cell therapy for sickle cell disease. Atlanta: 59th ASH Annual Meeting & Exposition; 2017."},{"key":"383_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.omtm.2018.08.003","volume":"10","author":"N Psatha","year":"2018","unstructured":"Psatha N, et al. Disruption of the BCL11A erythroid enhancer reactivates fetal hemoglobin in erythroid cells of patients with beta-thalassemia major. Mol Ther Methods Clin Dev. 2018;10:313\u201326.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"383_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.omtm.2018.09.001","volume":"11","author":"MR Lidonnici","year":"2018","unstructured":"Lidonnici MR, et al. Multiple integrated non-clinical studies predict the safety of lentivirus-mediated gene therapy for beta-thalassemia. Mol Ther Methods Clin Dev. 2018;11:9\u201328.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"9","key":"383_CR28","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","volume":"20","author":"HK Duong","year":"2014","unstructured":"Duong HK, et al. Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2014;20(9):1262\u201373.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"383_CR29","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.exphem.2006.06.003","volume":"34","author":"S Fruehauf","year":"2006","unstructured":"Fruehauf S, et al. The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol. 2006;34(8):1052\u20139.","journal-title":"Exp Hematol"},{"issue":"5","key":"383_CR30","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2015-03-629618","volume":"126","author":"G Karponi","year":"2015","unstructured":"Karponi G, et al. Plerixafor\u2009+\u2009G-CSF-mobilized CD34+\u2009cells represent an optimal graft source for thalassemia gene therapy. Blood. 2015;126(5):616\u20139.","journal-title":"Blood"},{"issue":"10","key":"383_CR31","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1182\/blood.V97.10.3313","volume":"97","author":"BK Adler","year":"2001","unstructured":"Adler BK, et al. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood. 2001;97(10):3313\u20134.","journal-title":"Blood"},{"issue":"12","key":"383_CR32","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1182\/blood.V97.12.3998","volume":"97","author":"AP Grigg","year":"2001","unstructured":"Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell\/beta\u2009+\u2009thalassemia. Blood. 2001;97(12):3998\u20139.","journal-title":"Blood"},{"issue":"9107","key":"383_CR33","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0140-6736(05)60614-9","volume":"351","author":"M Abboud","year":"1998","unstructured":"Abboud M, Laver J, Blau CA. Granulocytosis causing sickle-cell crisis. Lancet. 1998;351(9107):959.","journal-title":"Lancet"},{"issue":"1","key":"383_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/mt.2011.195","volume":"20","author":"E Yannaki","year":"2012","unstructured":"Yannaki E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe beta-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230\u20138.","journal-title":"Mol Ther"},{"key":"383_CR35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bcmd.2015.12.008","volume":"57","author":"E Choi","year":"2016","unstructured":"Choi E, et al. No evidence for cell activation or brain vaso-occlusion with plerixafor mobilization in sickle cell mice. Blood Cells Mol Dis. 2016;57:67\u201370.","journal-title":"Blood Cells Mol Dis"},{"key":"383_CR36","volume-title":"Successful plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease","author":"JF Tisdale","year":"2017","unstructured":"Tisdale JF, et al. Successful plerixafor-mediated mobilization, apheresis, and lentiviral vector transduction of hematopoietic stem cells in patients with severe sickle cell disease. GA: ASH 59th Annual Meeting and Exposition; 2017."},{"key":"383_CR37","volume-title":"Safety and efficacy trial of escalation of plerixafor for mobilization of CD34+\u2009hematopoietic progenitor cells (HPCs) for globin gene transfer in patients with sickle cell disease","author":"F Boulad","year":"2017","unstructured":"Boulad F, et al. Safety and efficacy trial of escalation of plerixafor for mobilization of CD34+\u2009hematopoietic progenitor cells (HPCs) for globin gene transfer in patients with sickle cell disease. Atlanta: ASH 59th Annual Meeting and Exposition; 2017."},{"issue":"19","key":"383_CR38","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/bloodadvances.2018016725","volume":"2","author":"EB Esrick","year":"2018","unstructured":"Esrick EB, et al. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Adv. 2018;2(19):2505\u201312.","journal-title":"Blood Adv"},{"issue":"7","key":"383_CR39","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","volume":"34","author":"R Palchaudhuri","year":"2016","unstructured":"Palchaudhuri R, et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol. 2016;34(7):738\u201345.","journal-title":"Nat Biotechnol"},{"issue":"13","key":"383_CR40","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1182\/blood-2003-04-1251","volume":"102","author":"DN Levasseur","year":"2003","unstructured":"Levasseur DN, et al. Correction of a mouse model of sickle cell disease: lentiviral\/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood. 2003;102(13):4312\u20139.","journal-title":"Blood"},{"issue":"22","key":"383_CR41","doi-asserted-by":"publisher","first-page":"14380","DOI":"10.1073\/pnas.212507099","volume":"99","author":"S Imren","year":"2002","unstructured":"Imren S, et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA. 2002;99(22):14380\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"383_CR42","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2010-08-300723","volume":"117","author":"A Wilber","year":"2011","unstructured":"Wilber A, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of beta-thalassemic CD34+\u2009cells after lentiviral vector-mediated gene transfer. Blood. 2011;117(10):2817\u201326.","journal-title":"Blood"},{"issue":"5","key":"383_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.exphem.2015.01.009","volume":"43","author":"F Urbinati","year":"2015","unstructured":"Urbinati F, et al. Potentially therapeutic levels of anti-sickling globin gene expression following lentivirus-mediated gene transfer in sickle cell disease bone marrow CD34+\u2009cells. Exp Hematol. 2015;43(5):346\u201351.","journal-title":"Exp Hematol"},{"key":"383_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.omtm.2018.10.014","volume":"11","author":"V Poletti","year":"2018","unstructured":"Poletti V, et al. Pre-clinical development of a lentiviral vector expressing the anti-sickling betaAS3 globin for gene therapy for sickle cell disease. Mol Ther Methods Clin Dev. 2018;11:167\u201379.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"383_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.2174\/1566523214666141127095336","volume":"15","author":"O Negre","year":"2015","unstructured":"Negre O, et al. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64\u201381.","journal-title":"Curr Gene Ther"},{"issue":"7313","key":"383_CR46","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","volume":"467","author":"M Cavazzana-Calvo","year":"2010","unstructured":"Cavazzana-Calvo M, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature. 2010;467(7313):318\u201322.","journal-title":"Nature"},{"issue":"5259","key":"383_CR47","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.272.5259.263","volume":"272","author":"L Naldini","year":"1996","unstructured":"Naldini L, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263\u20137.","journal-title":"Science"},{"issue":"11","key":"383_CR48","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","volume":"72","author":"T Dull","year":"1998","unstructured":"Dull T, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463\u201371.","journal-title":"J Virol"},{"issue":"18","key":"383_CR49","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1073\/pnas.1214441110","volume":"110","author":"D Finkelshtein","year":"2013","unstructured":"Finkelshtein D, et al. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci USA. 2013;110(18):7306\u201311.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"383_CR50","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1182\/blood-2014-02-558163","volume":"124","author":"A Girard-Gagnepain","year":"2014","unstructured":"Girard-Gagnepain A, et al. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood. 2014;124(8):1221\u201331.","journal-title":"Blood"},{"issue":"3","key":"383_CR51","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1128\/JVI.78.3.1219-1229.2004","volume":"78","author":"XY Zhang","year":"2004","unstructured":"Zhang XY, La Russa VF, Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J Virol. 2004;78(3):1219\u201329.","journal-title":"J Virol"},{"issue":"4","key":"383_CR52","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/mt.2009.282","volume":"18","author":"GD Trobridge","year":"2010","unstructured":"Trobridge GD, et al. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol Ther. 2010;18(4):725\u201333.","journal-title":"Mol Ther"},{"issue":"18","key":"383_CR53","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.1128\/JVI.00483-16","volume":"90","author":"S Malicorne","year":"2016","unstructured":"Malicorne S, et al. Genome-wide screening of retroviral envelope genes in the nine-banded armadillo (Dasypus novemcinctus, Xenarthra) reveals an unfixed chimeric endogenous betaretrovirus using the ASCT2 receptor. J Virol. 2016;90(18):8132\u201349.","journal-title":"J Virol"},{"issue":"23","key":"383_CR54","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/bloodadvances.2017007773","volume":"1","author":"C Levy","year":"2017","unstructured":"Levy C, et al. Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent. Blood Adv. 2017;1(23):2088\u2013104.","journal-title":"Blood Adv"},{"issue":"4","key":"383_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/BF01314897","volume":"75","author":"RJ Coelen","year":"1983","unstructured":"Coelen RJ, Jose DG, May JT. The effect of hexadimethrine bromide (Polybrene) on the infection of the primate retroviruses SSV 1\/SSAV 1 and BaEV. Arch Virol. 1983;75(4):307\u201311.","journal-title":"Arch Virol"},{"issue":"2\u20133","key":"383_CR56","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0301-4622(02)00057-1","volume":"97","author":"HE Davis","year":"2002","unstructured":"Davis HE, Morgan JR, Yarmush ML. Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes. Biophys Chem. 2002;97(2\u20133):159\u201372.","journal-title":"Biophys Chem"},{"issue":"2","key":"383_CR57","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/S0006-3495(04)74197-1","volume":"86","author":"HE Davis","year":"2004","unstructured":"Davis HE, et al. Charged polymers modulate retrovirus transduction via membrane charge neutralization and virus aggregation. Biophys J. 2004;86(2):1234\u201342.","journal-title":"Biophys J"},{"issue":"2","key":"383_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jviromet.2013.02.005","volume":"189","author":"D Fenard","year":"2013","unstructured":"Fenard D, et al. Infectivity enhancement of different HIV-1-based lentiviral pseudotypes in presence of the cationic amphipathic peptide LAH4-L1. J Virol Methods. 2013;189(2):375\u20138.","journal-title":"J Virol Methods"},{"issue":"1","key":"383_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1089\/hgtb.2013.090","volume":"25","author":"D Ingrao","year":"2014","unstructured":"Ingrao D, et al. Concurrent measures of fusion and transduction efficiency of primary CD34+\u2009cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers. Hum Gene Ther Methods. 2014;25(1):48\u201356.","journal-title":"Hum Gene Ther Methods"},{"issue":"5","key":"383_CR60","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1074\/jbc.M115.675033","volume":"291","author":"S Majdoul","year":"2016","unstructured":"Majdoul S, et al. Molecular determinants of Vectofusin-1 and its derivatives for the enhancement of lentivirally mediated gene transfer into hematopoietic stem\/progenitor cells. J Biol Chem. 2016;291(5):2161\u20139.","journal-title":"J Biol Chem"},{"key":"383_CR61","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.actbio.2017.10.009","volume":"64","author":"LS Vermeer","year":"2017","unstructured":"Vermeer LS, et al. Vectofusin-1, a potent peptidic enhancer of viral gene transfer forms pH-dependent alpha-helical nanofibrils, concentrating viral particles. Acta Biomater. 2017;64:259\u201368.","journal-title":"Acta Biomater"},{"issue":"45","key":"383_CR62","doi-asserted-by":"publisher","first-page":"18672","DOI":"10.1074\/jbc.M117.800813","volume":"292","author":"S Majdoul","year":"2017","unstructured":"Majdoul S, et al. Peptides derived from evolutionarily conserved domains in Beclin-1 and Beclin-2 enhance the entry of lentiviral vectors into human cells. J Biol Chem. 2017;292(45):18672\u201381.","journal-title":"J Biol Chem"},{"issue":"7","key":"383_CR63","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.exphem.2016.04.007","volume":"44","author":"N Psatha","year":"2016","unstructured":"Psatha N, Karponi G, Yannaki E. Optimizing autologous cell grafts to improve stem cell gene therapy. Exp Hematol. 2016;44(7):528\u201339.","journal-title":"Exp Hematol"},{"issue":"7147","key":"383_CR64","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/nature05883","volume":"447","author":"TE North","year":"2007","unstructured":"North TE, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447(7147):1007\u201311.","journal-title":"Nature"},{"issue":"4","key":"383_CR65","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.stemcr.2017.02.010","volume":"8","author":"E Zonari","year":"2017","unstructured":"Zonari E, et al. Efficient ex vivo engineering and expansion of highly purified human hematopoietic stem and progenitor cell populations for gene therapy. Stem Cell Rep. 2017;8(4):977\u201390.","journal-title":"Stem Cell Rep"},{"key":"383_CR66","doi-asserted-by":"crossref","unstructured":"Heffner GC, et al. Prostaglandin E2 increases lentiviral vector transduction efficiency of adult human hematopoietic stem and progenitor cells. Mol Ther. 2017.","DOI":"10.1016\/j.ymthe.2017.09.025"},{"issue":"4","key":"383_CR67","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood.V92.4.1131","volume":"92","author":"JF Tisdale","year":"1998","unstructured":"Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE, Dunbar CE. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998;92(4):1131\u201341.","journal-title":"Blood."},{"key":"383_CR68","unstructured":"Bhukhai K, et al. Ex vivo selection of transduced hematopoietic stem cells for gene therapy of beta-hemoglobinopathies. Mol Ther. 2017."},{"issue":"6034","key":"383_CR69","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/317230a0","volume":"317","author":"O Smithies","year":"1985","unstructured":"Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature. 1985;317(6034):230\u20134.","journal-title":"Nature."},{"issue":"10","key":"383_CR70","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901\u201310.","journal-title":"N Engl J Med"},{"issue":"20","key":"383_CR71","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.1093\/nar\/gkt714","volume":"41","author":"TJ Cradick","year":"2013","unstructured":"Cradick TJ, et al. CRISPR\/Cas9 systems targeting beta-globin and CCR5 genes have substantial off-target activity. Nucl Acids Res. 2013;41(20):9584\u201392.","journal-title":"Nucl Acids Res"},{"issue":"17","key":"383_CR72","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1182\/blood-2014-12-615948","volume":"125","author":"MD Hoban","year":"2015","unstructured":"Hoban MD, et al. Correction of the sickle cell disease mutation in human hematopoietic stem\/progenitor cells. Blood. 2015;125(17):2597\u2013604.","journal-title":"Blood"},{"issue":"2","key":"383_CR73","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/nar\/gkt947","volume":"42","author":"RA Voit","year":"2014","unstructured":"Voit RA, et al. Nuclease-mediated gene editing by homologous recombination of the human globin locus. Nucl Acids Res. 2014;42(2):1365\u201378.","journal-title":"Nucl Acids Res"},{"issue":"7","key":"383_CR74","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt.2916","volume":"32","author":"C Kuscu","year":"2014","unstructured":"Kuscu C, et al. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol. 2014;32(7):677\u201383.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"383_CR75","doi-asserted-by":"publisher","first-page":"7473","DOI":"10.1093\/nar\/gku402","volume":"42","author":"Y Lin","year":"2014","unstructured":"Lin Y, et al. CRISPR\/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucl Acids Res. 2014;42(11):7473\u201385.","journal-title":"Nucl Acids Res"},{"issue":"7","key":"383_CR76","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41591-018-0050-6","volume":"24","author":"RJ Ihry","year":"2018","unstructured":"Ihry RJ, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med. 2018;24(7):939\u201346.","journal-title":"Nat Med"},{"issue":"1","key":"383_CR77","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1038\/s41467-018-05843-9","volume":"9","author":"JM Crudele","year":"2018","unstructured":"Crudele JM, Chamberlain JS. Cas9 immunity creates challenges for CRISPR gene editing therapies. Nat Commun. 2018;9(1):3497.","journal-title":"Nat Commun"},{"key":"383_CR78","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","volume":"10","author":"VL Simhadri","year":"2018","unstructured":"Simhadri VL, et al. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol Ther Methods Clin Dev. 2018;10:105\u201312.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"383_CR79","doi-asserted-by":"crossref","unstructured":"Charesworth CT, et al. Identification of pre-existing adaptive immunity to Cas9 proteins in humans. BioRXiv [Preprint] 2018.","DOI":"10.1101\/243345"},{"issue":"1","key":"383_CR80","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41467-017-00479-7","volume":"8","author":"S Mettananda","year":"2017","unstructured":"Mettananda S, Fisher CA, Hay D, Badat M, Quek L, Clark K, Hublitz P, et al. Editing an \u03b1-globin enhancer in primary human hematopoietic stem cells as a treatment for \u03b2-thalassemia. Nat Commun. 2017;8(1):424.","journal-title":"Nat Commun."},{"issue":"9","key":"383_CR81","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/mt.2016.148","volume":"24","author":"MD Hoban","year":"2016","unstructured":"Hoban MD, et al. CRISPR\/Cas9-mediated correction of the sickle mutation in human CD34+\u2009cells. Mol Ther. 2016;24(9):1561\u20139.","journal-title":"Mol Ther"},{"issue":"360","key":"383_CR82","doi-asserted-by":"publisher","first-page":"360ra134","DOI":"10.1126\/scitranslmed.aaf9336","volume":"8","author":"MA DeWitt","year":"2016","unstructured":"DeWitt MA, et al. Selection-free genome editing of the sickle mutation in human adult hematopoietic stem\/progenitor cells. Sci Transl Med. 2016;8(360):360ra134.","journal-title":"Sci Transl Med"},{"issue":"7629","key":"383_CR83","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever DP, et al. CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539(7629):384\u20139.","journal-title":"Nature"},{"key":"383_CR84","volume-title":"Preclinical development of HBB gene correction in autologous hematopoietic stem and progenitor cells to treat severe sickle cell disease","author":"DP Dever","year":"2017","unstructured":"Dever DP, et al. Preclinical development of HBB gene correction in autologous hematopoietic stem and progenitor cells to treat severe sickle cell disease. Atlanta: 59th ASH Annual Meeting and Exposition; 2017."},{"key":"383_CR85","doi-asserted-by":"publisher","first-page":"e04766","DOI":"10.7554\/eLife.04766","volume":"3","author":"S Lin","year":"2014","unstructured":"Lin S, et al. Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery. Elife. 2014;3:e04766.","journal-title":"Elife"},{"issue":"4","key":"383_CR86","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1089\/hgtb.2014.043","volume":"25","author":"A Gu","year":"2014","unstructured":"Gu A, et al. Engraftment and lineage potential of adult hematopoietic stem and progenitor cells is compromised following short-term culture in the presence of an aryl hydrocarbon receptor antagonist. Hum Gene Ther Methods. 2014;25(4):221\u201331.","journal-title":"Hum Gene Ther Methods"},{"issue":"12","key":"383_CR87","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt.3408","volume":"33","author":"J Wang","year":"2015","unstructured":"Wang J, et al. Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol. 2015;33(12):1256\u201363.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"383_CR88","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3324\/haematol.2010.031013","volume":"96","author":"M Andreani","year":"2011","unstructured":"Andreani M, et al. Quantitatively different red cell\/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica. 2011;96(1):128\u201333.","journal-title":"Haematologica"},{"issue":"17","key":"383_CR89","doi-asserted-by":"publisher","first-page":"4599","DOI":"10.1182\/blood-2011-02-335554","volume":"118","author":"J Zou","year":"2011","unstructured":"Zou J, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood. 2011;118(17):4599\u2013608.","journal-title":"Blood"},{"issue":"1","key":"383_CR90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/sctm.17-0066","volume":"7","author":"L Cai","year":"2018","unstructured":"Cai L, et al. A universal approach to correct various HBB gene mutations in human stem cells for gene therapy of beta-thalassemia and sickle cell disease. Stem Cells Transl Med. 2018;7(1):87\u201397.","journal-title":"Stem Cells Transl Med"},{"issue":"7681","key":"383_CR91","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli NM, et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature. 2017;551(7681):464\u201371.","journal-title":"Nature"},{"issue":"6366","key":"383_CR92","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1126\/science.aaq0180","volume":"358","author":"DBT Cox","year":"2017","unstructured":"Cox DBT, et al. RNA editing with CRISPR-Cas13. Science. 2017;358(6366):1019\u201327.","journal-title":"Science"},{"issue":"5","key":"383_CR93","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1073\/pnas.0711566105","volume":"105","author":"M Uda","year":"2008","unstructured":"Uda M, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"24","key":"383_CR94","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1056\/NEJM198212093072401","volume":"307","author":"TJ Ley","year":"1982","unstructured":"Ley TJ, et al. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta\u2009+\u2009thalassemia. N Engl J Med. 1982;307(24):1469\u201375.","journal-title":"N Engl J Med"},{"issue":"4","key":"383_CR95","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood.V63.4.921.921","volume":"63","author":"DR Powars","year":"1984","unstructured":"Powars DR, et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood. 1984;63(4):921\u20136.","journal-title":"Blood"},{"issue":"3","key":"383_CR96","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00439-009-0770-2","volume":"127","author":"M Nuinoon","year":"2010","unstructured":"Nuinoon M, et al. A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia\/hemoglobin E. Hum Genet. 2010;127(3):303\u201314.","journal-title":"Hum Genet"},{"issue":"3","key":"383_CR97","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1365-2141.2006.06408.x","volume":"136","author":"L Quek","year":"2007","unstructured":"Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haematol. 2007;136(3):353\u201365.","journal-title":"Br J Haematol"},{"issue":"10","key":"383_CR98","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","volume":"79","author":"S Charache","year":"1992","unstructured":"Charache S, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood. 1992;79(10):2555\u201365.","journal-title":"Blood"},{"issue":"9","key":"383_CR99","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm.4170","volume":"22","author":"EA Traxler","year":"2016","unstructured":"Traxler EA, et al. A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat Med. 2016;22(9):987\u201390.","journal-title":"Nat Med"},{"issue":"5909","key":"383_CR100","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1126\/science.1165409","volume":"322","author":"VG Sankaran","year":"2008","unstructured":"Sankaran VG, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839\u201342.","journal-title":"Science"},{"issue":"10","key":"383_CR101","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1172\/JCI87885","volume":"126","author":"C Brendel","year":"2016","unstructured":"Brendel C, et al. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest. 2016;126(10):3868\u201378.","journal-title":"J Clin Invest"},{"key":"383_CR102","volume-title":"Introduction of two simultaneous mutations by genome editing greatly enhances the accumulation of the endogenous fetal hemoglobin in human normal erythroid cells","author":"N Psatha","year":"2017","unstructured":"Psatha N, et al. Introduction of two simultaneous mutations by genome editing greatly enhances the accumulation of the endogenous fetal hemoglobin in human normal erythroid cells. Atlanta: 59th ASH Annual Meeting and Exposition; 2017."},{"key":"383_CR103","volume-title":"RISPR\/Cas9 genome editing to treat sickle cell disease and B-thalassemia: re-creating genetic variants to upregulate fetal hemoglobin appear well-tolerated, effective and durable","author":"MI Lin","year":"2017","unstructured":"Lin MI, et al. RISPR\/Cas9 genome editing to treat sickle cell disease and B-thalassemia: re-creating genetic variants to upregulate fetal hemoglobin appear well-tolerated, effective and durable. GA: 59th ASH Annual Meeting and Exposition; 2017."},{"key":"383_CR104","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1038\/mtna.2016.52","volume":"5","author":"CF Bjurstrom","year":"2016","unstructured":"Bjurstrom CF, et al. Reactivating fetal hemoglobin expression in human adult erythroblasts through BCL11A knockdown using targeted endonucleases. Mol Ther Nucl Acids. 2016;5:e351.","journal-title":"Mol Ther Nucl Acids"},{"key":"383_CR105","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.omtm.2016.12.009","volume":"4","author":"KH Chang","year":"2017","unstructured":"Chang KH, et al. Long-term engraftment and fetal globin induction upon BCL11A gene editing in bone-marrow-derived CD34(+) hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev. 2017;4:137\u201348.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"383_CR106","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1016\/j.celrep.2016.08.064","volume":"16","author":"S Luc","year":"2016","unstructured":"Luc S, et al. Bcl11a deficiency leads to hematopoietic stem cell defects with an aging-like phenotype. Cell Rep. 2016;16(12):3181\u201394.","journal-title":"Cell Rep"},{"key":"383_CR107","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13059-015-0739-5","volume":"16","author":"JC Tsang","year":"2015","unstructured":"Tsang JC, et al. Single-cell transcriptomic reconstruction reveals cell cycle and multi-lineage differentiation defects in Bcl11a-deficient hematopoietic stem cells. Genome Biol. 2015;16:178.","journal-title":"Genome Biol"},{"issue":"4","key":"383_CR108","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.cell.2014.05.050","volume":"158","author":"W Deng","year":"2014","unstructured":"Deng W, et al. Reactivation of developmentally silenced globin genes by forced chromatin looping. Cell. 2014;158(4):849\u201360.","journal-title":"Cell"},{"issue":"8","key":"383_CR109","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood-2016-01-691089","volume":"128","author":"L Breda","year":"2016","unstructured":"Breda L, et al. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers. Blood. 2016;128(8):1139\u201343.","journal-title":"Blood"},{"issue":"9","key":"383_CR110","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/ng.630","volume":"42","author":"J Borg","year":"2010","unstructured":"Borg J, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet. 2010;42(9):801\u20135.","journal-title":"Nat Genet"},{"issue":"11","key":"383_CR111","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1182\/bloodadvances.2016002303","volume":"1","author":"LJ Norton","year":"2017","unstructured":"Norton LJ, et al. KLF1 directly activates expression of the novel fetal globin repressor ZBTB7A\/LRF in erythroid cells. Blood Adv. 2017;1(11):685\u201392.","journal-title":"Blood Adv"},{"issue":"3","key":"383_CR112","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/ehm.13.24","volume":"6","author":"L Breda","year":"2013","unstructured":"Breda L, et al. Combining gene therapy and fetal hemoglobin induction for treatment of beta-thalassemia. Exp Rev Hematol. 2013;6(3):255\u201364.","journal-title":"Exp Rev Hematol"},{"issue":"15","key":"383_CR113","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1182\/blood-2010-11-316893","volume":"117","author":"A Wilber","year":"2011","unstructured":"Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood. 2011;117(15):3945\u201353.","journal-title":"Blood"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40291-019-00383-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-019-00383-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-019-00383-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T19:21:14Z","timestamp":1580325674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40291-019-00383-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":113,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1007\/s40291-019-00383-4","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"30 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"LB, VG and MC declare no conflict of interest. SR is a consultant for Ionis Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review was made possible through the collaboration of LB and SR in the THALAssaemia MOdular Stratification System for personalized therapy of \u03b2-thalassemia (THALAMOSS), European Community: FP7-HEALTH-2012-INNOVATION. This work is supported by grants from the National Institutes of Health (NIDDK-R01DK090554 and NIDDK-R01DK095112 to S.R.). The authors gratefully acknowledge the generous support by the Jean, Schejola and Di Gaetano families and the Children\u2019s Hospital of Philadelphia Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}